

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported) January 25, 2006

Nabi Biopharmaceuticals

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-04829

59-1212264

(Commission File Number)

(IRS Employer Identification No.)

**5800 Park of Commerce Boulevard N.W.,
Boca Raton, FL**

02324

(Address of Principal Executive Offices)

(Zip Code)

(561) 989-5800

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On January 25, 2006, Mark L. Smith resigned effective on or about March 1, 2006 as Nabi Biopharmaceutical's Senior Vice President, Finance, Chief Financial Officer, Chief Accounting Officer and Treasurer in order to accept another opportunity. This timing will support the filing of the company's Form 10-K. Mr. Smith's resignation was not related to any disagreement or dispute with the company's management. The company has begun a search for Mr. Smith's successor.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NABI BIOPHARMACEUTICALS

Date: January 27, 2006

By: /s/ Thomas H. McLain
Name: Thomas H. McLain,
Chairman, Chief Executive Officer and President